NVAXMEDIUM SIGNALFINANCIAL10-K

NVAX demonstrated strong revenue growth while meaningfully reducing operational expenses and improving its balance sheet structure.

The company appears to be successfully executing a turnaround strategy, generating substantially higher revenue while implementing significant cost discipline. The reduction in current liabilities by over 60% and improvement in stockholders' equity position suggests better financial stability, though the company remains in a deficit equity position requiring continued monitoring.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

NVAX showed robust revenue growth alongside disciplined expense management, with SG&A expenses declining substantially. The balance sheet demonstrated meaningful improvement with current liabilities reduced by over 60% and stockholders' equity moving closer to positive territory, though cash reserves declined by approximately half. Overall, the financial picture suggests a company in transition toward improved operational efficiency and financial stability.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-83.9%
$1.4M→$233K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
+79.5%
-$623.8M→-$127.8M

Equity base grew 79.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
+64.7%
$682.2M→$1.1B

Strong top-line growth of 64.7% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
-60.2%
$1.2B→$459.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-54.6%
$530.2M→$240.6M

Cash declined 54.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

SG&A Expense
P&L
-53.3%
$337.2M→$157.5M

SG&A reduced 53.3% — improved cost efficiency or headcount reduction improving operating margins.

Total Liabilities
Balance Sheet
-40.3%
$2.2B→$1.3B

Liabilities reduced 40.3% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
+32%
$8.7M→$11.5M

Inventory surged 32% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Interest Expense
P&L
-27.5%
$19.9M→$14.4M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Assets
Balance Sheet
-24.6%
$1.6B→$1.2B

Total assets contracted 24.6% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 16, 2026, there were 162,935,945 shares of the registrant s common stock outstanding.
All references in this Annual Report on Form 10-K to Nuvaxovid TM or COVID-19 Vaccine refer to the Nuvaxovid COVID-19 vaccine; all references to "JN.1 COVID-19 Vaccine" refer to the Nuvaxovid TM COVID-19 Vaccine for the 2025-2026 vaccination season.
SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to numerous risks.
The following is a summary of the principal risk factors described in this section: We have a history of losses and our future profitability is uncertain.
Our existing collaboration, funding and supply agreements, including the Sanofi CLA and our APAs, do not assure success of our vaccine candidates or vaccines or that we will be able to fully fund our vaccine candidates or vaccines or our operations, and if we are unable to satisfy the performance obligations under such agreements, we may not be eligible to receive milestone payments under such agreements, the agreements may be terminated, the purchase commitments may be reduced or we may be required to refund advance payments.
+7 more — sign up free →
REMOVED
As of February 18, 2025, there were 160,844,197 shares of the Registrant s common stock outstanding.
FORM 10-K SUMMARY 95 2 Table o f Contents CERTAIN DEFINITIONS All references in this Annual Report on Form 10-K to Novavax, the Company, we, us, and our refer to Novavax, Inc.
All references in this Annual Report on Form 10-K to "NVX-CoV2373 or prototype COVID-19 vaccine refer to our Nuvaxovid prototype COVID-19 vaccine; all references to "NVX-CoV2601" or "XBB COVID-19 vaccine" refer to our Nuvaxovid TM COVID-19 vaccine for the 2023-2024 vaccination season; and all references to "NVX-CoV2705", "JN.1 COVID-19 vaccine" or updated COVID-19 vaccine refer to our Nuvaxovid TM COVID-19 vaccine for the 2024-2025 vaccination season.
We refer to our prototype COVID-19 vaccine and updated COVID-19 vaccines, collectively, as our COVID-19 vaccine .
Local regulatory authorities have also specified nomenclature for our COVID-19 vaccine for labeling within their territories (e.g., Novavax COVID-19 Vaccine, Adjuvanted , Novavax COVID-19, Adjuvanted (2023-2024 or 2024-2025 Formula), respectively, for the U.S., and Nuvaxovid for ex-U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →